Recently, Alosenta had the pleasure of speaking at the #UK–#Japan Connect event, hosted by Grow London Global.
Momentum continues to build around UK–Japan collaboration in life sciences and deep tech. For Alosenta, Japan represents a highly sophisticated scientific and industrial ecosystem, with a strong commitment to translating innovation into real patient impact.
Our Commercial Development Executive, Judy Kingswolf-Yamakawa, spoke during the afternoon pitch session, sharing Alosenta’s approach to pipeline growth and how we address one of the industry’s most persistent challenges: drug toxicity. With ~90% of clinical trial failures linked to toxicity, our work focuses on reducing this risk across the full therapeutic lifecycle—from early-stage drug discovery through to targeted drug delivery.
Great panel discussions around:
- Building trust before commercial engagement
- Structuring early partnerships for long-term value
- Aligning UK innovation speed with Japanese corporate timelines
- Thinking beyond market entry towards sustained ecosystem integration
Thank you to the Grow London Global and wider London & Partners team for convening such a high-quality group, and to the speakers and panellists for sharing such open and practical insights.